Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Renal cell carcinoma (RCC) is by far the most common type of kidney cancer. About 9 out of 10 kidney cancers are renal cell carcinomas.
Although RCC usually grows as a single mass (tumor) within a kidney, sometimes there are 2 or more tumors in one kidney or even tumors in both kidneys at the same time. Some of these cancers are noticed only after they have become quite large, but most are found before they metastasize (spread) to distant organs in the body.
Transitional cell carcinoma
Of every 100 cancers in the kidney, about 5 to 10 are transitional cell carcinomas, also known as urothelial carcinomas. Transitional cell carcinomas don't start in the kidney itself, but instead begin in the renal pelvis (where the urine goes before it enters the ureter). About 9 out of 10 transitional cell carcinomas of the kidney are curable if they are found at an early stage.
Nephroblastomas, more commonly called Wilms tumors, almost always occur in children. This type of cancer is very rare among adults.
Renal sarcomas are a rare type of kidney cancer (less than 1% of all kidney tumors) that begin in the blood vessels or connective tissue of the kidney.
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.